TMC114 (Darunavir, Prezista): News
- Prezista (Darunavir) Label Change -- Drug Interaction Information (March 1, 2013)
From U.S. Food and Drug Administration
- New 800-mg Prezista (January/February 2013)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
 The 800-mg Darunavir Tablet Arrives, and Scoring the Top Protease Inhibitors (November 18, 2012)
From Journal Watch
On TheBodyPRO.com
- Much More Than Just Following Your Doctor's Orders (July 12, 2012)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- FDA Approve Pediatric Dose for Darunavir (January/February 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- Updated Information About Prezista (Darunavir): Oral Suspension and Labeling Changes (December 20, 2011)
From U.S. Food and Drug Administration
- Gilead and Tibotec Agree on New Single-Tablet Regimen (November 23, 2011)
In Positively Aware, from Test Positive Aware Network
- Gilead and J&J Expand HIV Cocktail Partnership (November 16, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Tibotec and Gilead Team Up to Develop Prezista/Cobicistat Combo (July 5, 2011)
From Test Positive Aware Network
- Musty Smell Forces Johnson & Johnson to Recall HIV/AIDS Drug (May 12, 2011)
In Los Angeles Times
- Johnson & Johnson Unit Finds Traces of Fungicide in HIV Drug (May 11, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- MSF Letter Criticizes Johnson & Johnson for Not Joining Medicines Patent Pool (April 26, 2011)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- For Some, Taking Prezista Once a Day Is Enough (February 2011)
To read PDF, click here.
In Project Inform Perspective, from Project Inform
- FDA Approves Once-Daily Prezista Dosing for Treatment-Experienced Adults (December 13, 2010)
From U.S. Food and Drug Administration
- National Institutes of Health Donates Protease Inhibitor Patent to UNITAID Medicines Patent Pool (Autumn 2010)
To read PDF, click here.
In TAGline, from Treatment Action Group
- U.S. Food and Drug Administration Approves Labeling Update for Prezista to Include 96-Week Data in HIV-1 Infected Adult Patients (January 28, 2010)
From Tibotec Therapeutics
- Prezista Now Available for Pediatric Patients Six Years of Age and Older as Part of HIV Combination Therapy (February 11, 2009)
From Tibotec Therapeutics
- New 75 mg Prezista Tablet and Corresponding Pediatric Dosing Information Approved (December 18, 2008)
From U.S. Food and Drug Administration
- HIV/AIDS Update - Important information about Prezista (darunavir) (October 22, 2008)
From U.S. Food and Drug Administration
- Updates to Prezista (Darunavir) Tablets Labeling (March 11, 2008)
From U.S. Food and Drug Administration
- "Dear Healthcare Professional" Letter: New Prescribing Information for Prezista (Darunavir) (March 2008)
Labeling has been updated to include warnings regarding hepatotoxicity.
From Tibotec Therapeutics
|
Advertisement
|
Email
Glossary
